83 related articles for article (PubMed ID: 26546451)
1. Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer.
Mulligan AM; Pinnaduwage D; Tchatchou S; Bull SB; Andrulis IL
Cancer Immunol Res; 2016 Jan; 4(1):41-8. PubMed ID: 26546451
[TBL] [Abstract][Full Text] [Related]
2. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
4. T-box transcription factor 21 expression in breast cancer and its relationship with prognosis.
Yu H; Yang J; Jiao S; Li Y; Zhang W; Wang J
Int J Clin Exp Pathol; 2014; 7(10):6906-13. PubMed ID: 25400774
[TBL] [Abstract][Full Text] [Related]
5. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
6. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
7. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Srivastava AN; Makker A; Goel MM
Indian J Cancer; 2013; 50(3):239-44. PubMed ID: 24061465
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma.
Kwon HJ; Choi JE; Kang SH; Son Y; Bae YK
Histopathology; 2017 Jun; 70(7):1155-1165. PubMed ID: 28178752
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
11. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization.
Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
Cancer; 2012 Feb; 118(4):914-23. PubMed ID: 21800290
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
13. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
[TBL] [Abstract][Full Text] [Related]
14. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
19. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
20. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.
Miyan M; Schmidt-Mende J; Kiessling R; Poschke I; de Boniface J
J Transl Med; 2016 Jul; 14(1):227. PubMed ID: 27473163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
